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Abstract
Social audits are typically observational studies, combining qualitative and quantitative uptake of evidence with
consultative interpretation of results. This often falters on issues of causality because their cross-sectional design
limits interpretation of time relations and separation out of other indirect associations.
Social audits drawing on methods of randomised controlled cluster trials (RCCT) allow more certainty about
causality. Randomisation means that exposure occurs independently of all events that precede it – it converts
potential confounders and other covariates into random differences. In 2008, CIET social audits introduced
randomisation of the knowledge translation component with subsequent measurement of impact in the changes
introduced. This “proof of impact” generates an additional layer of evidence in a cost-effective way, providing
implementation-ready solutions for planners.
Pipeline planning is a social audit that incorporates stepped wedge RCCTs. From a listing of districts/communities
as a sampling frame, individual entities (communities, towns, districts) are randomly assigned to waves of
intervention. Measurement of the impact takes advantage of the delay occasioned by the reality that there are
insufficient resources to implement everywhere at the same time. The impact in the first wave contrasts with the
second wave, which in turn contrasts with a third wave, and so on until all have received the intervention.
Provided care is taken to achieve reasonable balance in the random allocation of communities, towns or districts
to the waves, the resulting analysis can be straightforward.
Where there is sufficient management interest in and commitment to evidence, pipeline planning can be
integrated in the roll-out of programmes where real time information can improve the pipeline. Not all
interventions can be randomly allocated, however, and random differences can still distort measurement. Other
issues include contamination of the subsequent waves, ambiguity of indicators, “participant effects” that result from
lack of blinding and lack of placebos, ethics and, not least important, the skills to do pipeline planning correctly.
Introduction
CIET social audit methods originated in the mid-1980s in
Central America [1-3] as an attempt to generate reliable
evidence on the coverage of key interventions and their
presumptive outcomes. This first generation of social
audit focussed on simple indicators and stakeholder dis-
cussions about what these might mean and what could be
done about them [4]. The aim was not to prove causality,
but to begin discussions with communities and planners
about what worked and how.
A second generation of social audits strengthened
methods of feedback of evidence to stakeholders in
communities and health services, and collated a second
order of evidence: what communities and service workers
felt could be done about the problems identified in the
household surveys. Just as we aggregated, for example,
low vaccination rates and costs of measles [5] across an
epidemiological sample, we could aggregate community-
led solutions to these problems.
These first two generations of social audits relied on
observational studies that combined qualitative and
quantitative uptake of evidence with consultative inter-
pretation of results. Because of this design, subsequent
discussions often stumbled over issues of causality.
In 2008, as part of the five year Nigeria Evidence-based
Health System Initiative (NEHSI) in Bauchi and Cross
River states [http://www.idrc.ca/EN/Programs/Global_
Health_Policy/Governance_for_Equity_in_Health_System-
s/Pages/ProjectDetails.aspx?ProjectNumber=104613], social
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any medium, provided the original work is properly cited.audits introduced randomisation of the knowledge transla-
tion component, with subsequent measurement of impact
of the changes introduced. The state governments nomi-
nated maternal outcomes as their first health priority for
study. In each state, a random sample of 60 sites provided
state level representation for a baseline survey of maternal
morbidity. In addition, 10 randomly selected sites in each
of three randomly selected focus local government authori-
ties (LGA) in each state, provided increased sensitivity of
local analysis. Preliminary analysis involved dozens of state
and LGA level health managers, who analysed and dis-
cussed results in a training setting. Field teams took the
emerging evidence into gender stratified discussions in
each of the 180 sites. Facilitators asked questions and used
standardized prompts to elicit responses.
The most consistent and prominent of 28 candidate risk
factors for non-fatal maternal morbidity was intimate part-
ner violence (IPV) during pregnancy (ORa 2.15, 95%CIca
1.43-3.24 in Bauchi and ORa 1.5, 95%CI 1.20-2.03 in
Cross River). Other spouse-related factors in the multivari-
ate model included not discussing pregnancy primarily
with the spouse and, independently, IPV in the last year.
The social audit concluded that the violence women
experience throughout their lives – genital mutilation,
domestic violence, and the effects of steep power gradients
– is accentuated through pregnancy and childbirth, when
women are most vulnerable. IPV especially in pregnancy,
women’s fear of husbands or partners and not discussing
pregnancy are all within men’s capacity to change. Few
women had a say in where they would deliver their
children.
These preliminary results fed into gender-stratified focus
group discussions in each site. Sharing the results with
participants, facilitators asked questions and used standar-
dized prompts and monitors recorded the separate male
and female discussions about work during pregnancy, safe
pregnancy and safe birth, IPV and female genital mutila-
tion (FGM).
The preliminary analysis and focus group discussions
focussed on solutions that increase male responsibility
around pregnancy and childbirth. First, a video drama
(separate for each state) showed a woman with pregnancy
problems mistreated by her husband; this supported
structured discussions within each site, to arrive at a ser-
ies of local solutions. Second, local health workers
received a scorecard of local indicators related to mater-
nal morbidity, and viewed the video drama. They also
received training in primary prevention strategies
focussed on men. Third, all pregnant women in the sam-
ple sites received several visits from health workers and
traditional birth attendants. They asked about current
health, safety and access to care of each pregnant
woman. A separate interview with the husband or part-
ner asked about potential ways to reduce heavy work in
pregnancy, the issue of violence in pregnancy, and how
to encourage discussion of pregnancy between husband
and wife.
In the sample based social audit, we intended these three
strategies to generate community-led solutions that could
feed in to LGA plans and, with the roll-up of the sample,
state authorities. As it turned out, the process of generat-
ing the intervention itself had the potential to decrease
maternal morbidity in the six randomly selected LGAs.
This “proof of impact” is a third order of evidence pro-
duced in a cost-effective way, providing implementation-
ready solutions for planners at state level.
Quantitative evidence and emergence of pragmatic
randomised controlled trials
In the 1990s, the New Public Administration approach in
the USA attempted to make it normal to provide “definite
and quantitative evidence” [6]. With the increasing
demand for high quality evidence, methods of social audit
[7] have evolved beyond public opinion polls and observa-
tional studies, to include techniques like randomised con-
trolled trials (RCTs). These trials (experiments), which
involve using comparisons with people or places that do
not receive the intervention in question (controls), rely on
random allocation of the intervention to generate convin-
cing evidence of impact or lack of impact.
The international evaluation industry has heard loud
voices of those who say impact is measurable and provable
[8-10] – among other ways, using RCTs – and those who
are overcome by the many practical and theoretical diffi-
culties of this proposition [11-13].
It has become a cliché to claim that controlled trials are
the only design that can account for selection bias and
demonstrate a causal relationship between intervention
and outcomes [14-16]. Several issues affect application of
RCT methods in the area of policy. There may be ethical
issues of withholding interventions in control commu-
nities [17]. Biases can result from health workers and com-
munities alike knowing what the interventions are [18]
and there are difficulties of appropriate analysis [19].
Other problems include the often changing contexts of
interventions, logistical and practical challenges, difficulties
with monitoring service delivery, access to the intervention
by the comparison group and changes in selection criteria
and/or the intervention over time [20].
Elaboration of pragmatic RCTs over the last 10-15
years has addressed and clarified many of the issues
associated with RCT-related methods in the realm of
policy [21-25].
Much of the difference between explanatory and prag-
matic trials can be summarised by the questions they try
to answer. An explanatory RCT might ask, “Can this vac-
cine have a protective effect under ideal conditions?”
Pragmatic RCTs typically apply interventions we know to
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and might ask the next question, “How well does this
vaccine actually work in real life?” [26].
The emergence of pragmatic trials has implications for
evidence-based planning. First, randomising and compari-
son with a control group are the principal contributions of
pragmatic RCTs, not double blinding or placebos [27,28].
Apart from the considerable advantage of experiments
that they arrange the exposure to precede the outcome,
the pivotal value of randomising in health policy and plan-
ning is that this converts covariants into random differ-
ences that can be assessed formally using standard
statistical procedures [29-31]. Randomisation means that
everything associated with the outcome prior to the expo-
sure is independent of the exposure. This shifts the oner-
ous burden of proof of observational studies, where the
researcher is obliged to exclude potential confounders one
by one as possible explanations of a presumed effect.
An important advantage of pragmatic trials is the ability
to contemplate real life costs to health services and to the
intended beneficiaries. They also allow consideration of
unintended effects, positive and negative. In most prag-
matic trials, the unit of randomisation, intervention and
analysis is the cluster: the community or a segment of it.
These randomised controlled cluster trials (RCCT) have
an interesting application in contemporary social audit.
Pipeline planning and social audit
Social audits have incorporated the elements of pragmatic
RCCTs; pipeline planning refers to the real time use of
evidence from this type of social audit to fine tune inter-
ventions in the programme pipeline. The idea behind
pipeline planning is simple and compelling: in the frame-
work of a pragmatic RCCT, implement an intervention in
an initial wave of randomly selected places; then, after an
appropriate interval, measure the impact of this in com-
parison with the second wave, before they start the inter-
vention. In successive waves of intervention, each is
contrasted with a previous wave. Each new wave and mea-
surement generates high quality evidence on impact and
intermediate outcomes (such as risk behaviours). This
information can feed into adjustments of the next wave of
the intervention – the pipeline – fine tuning it to optimise
its impact.
As an example, a concern to deal with unofficial pay-
ments and staff attitudes in health services might begin
with a national baseline survey that documents payments
and views of the public about government services
[5,32-35]. Informed by this community input, candidate
interventions might be discussed with service workers
and planners. These can be implemented in an initial
wave of sites – perhaps the original sample sites – and
then rolled out through successive waves, the baseline of
each wave on commencement serving as the “control”
for the last intervention wave. A similar approach can be
relevant to roll out of interventions across a wide range
of health issues – HIV prevention, diabetes or hyperten-
sion care.
In parallel with the rollout of the intervention, a dialogue
with research users (in our social audits, planners, service
workers and communities) should increase engagement
on emerging evidence of the impact of the candidate inter-
vention; cultural and contextual aspects to prevention,
especially local (if forgotten) resilience behaviours in the
various cultural groups; neglected aspects of current pre-
vention efforts, for example choice disability (when people
are unable to implement protective choices).
The stepped-wedge RCCT is a pragmatic trial design
that compares an initial wave of randomly selected indivi-
duals or clusters with successive waves that join the inter-
vention at intervals, until all have been included. Random
allocation of similar sets to each wave has the same effect
as randomisation in a simple randomised controlled trial:
exposure occurs independent of all the events that precede
it. The key assumption is that each wave selected to
receive the intervention in the future is similar to the
initial intervention, and therefore comparable in terms of
the outcome of interest.
Technical aspects: pipeline planning of the reduction of
maternal morbidity in Nigeria
The same three components of community engagement
on maternal morbidity in Nigeria will be rolled out as a
stepped-wedge randomised controlled trial across the
remaining 17 LGAs in Bauchi state; the intervention was
piloted in three randomly selected LGAs. This will be
conducted in two waves, two years apart, with eight
LGAs randomly assigned to each wave. Implementation
detail of this helps to illustrate the mechanisms and logis-
tics of pipeline planning.
A brief baseline household census will contact every
household in the LGA, to identify women who have been
pregnant in the last two years and women who are cur-
rently pregnant. The interviewer will ask those who have
been pregnant in the last year to provide information
about risk factors and maternal morbidity, using a shor-
tened version of the social audit questionnaire. In parallel,
all clinic and health facility records will be collated and
reviewed to establish the maternal mortality in the LGA in
the previous two years. Supplementary sources of informa-
tion about maternal mortality will include funeral parlours
and religious leaders who conduct burials. In each LGA,
the programme will involve several steps geared to
increase acceptance of the responsibility of men in mater-
nal morbidity and mortality.
Evidence from the social audit will be shared with all
residents of the first randomly selected LGAs (eight per
state) through the three channels developed during the
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phase of the social audit:
1. the video drama will be shown in all communities
in the LGA, and used on local television and in schools
to generate discussions about men and pregnancy;
2. health workers across the entire LGA will receive
orientation on primary prevention of maternal morbid-
ity, in addition to revision of danger signs in pregnancy,
and their management;
3. every pregnant woman and her husband or partner,
identified during the baseline survey, will receive several
visits in the course of the pregnancy; these visits will
extend to other women who become pregnant, identi-
fied through networking among pregnant women.
At the end of two years, a repeat census will contact
every household in the first wave LGAs and all households
in the second wave LGAs. Again, this will identify women
who have been pregnant in the last two years, and those
currently pregnant. As in the baseline, collation of health
facility records, funeral homes and religious leaders will
attempt to document maternal mortality. This repeat cen-
sus will provide the baseline for the second wave will
allow assessment of the impact of the intervention on
maternal morbidity and mortality in the first wave.
After the baseline census in the first wave of LGAs, ana-
lysis of the difference between these and the six randomly
selected pilot LGAs will allow for fine tuning of the inter-
vention prior to its rollout. Again when the first wave and
second wave are compared two years later, the analysis
will inform fine tuning of the intervention, adding new
components or modifying existing components. At this
point it will also be possible to assess the first six randomly
selected LGAs to see what happens two years after their
intervention ended.
Sample size computations
In pipeline planning, sample size computations are illus-
trative of the level of power available rather than the
part of the rationale for going ahead with the trial. In
Bauchi state, there are around 800,000 households. The
average LGA (40,000 households) should see around
10,000 pregnancies and 800 maternal deaths each year.
Treating maternal mortality as a continuous variable
(cluster size 10,000, SD 0.35, ICC 0.15, 0.8 power, 0.05
significance) we anticipate eight clusters per wave could
detect a 20% reduction in maternal mortality. Because
maternal morbidity is more common, affecting nearly
one half of the women, this design would be adequate
to pick up a 10% reduction in maternal morbidity (clus-
ter size 10,000, SD 0.18, ICC 0.15, 0.8 power, 0.05
significance).
Logistics
The intervention is labour intensive, requiring the hiring
and training of around 300 people in Bauchi state. In
each wave, each household will receive one visit each
year to identify pregnant women and outcomes in the
previous two years. Each pregnant woman will receive
four monthly visits each pregnancy. This comes to some
80,000 household visits each year per LGA – 10 visits
per day, 20 working days per month, for each of 33 tra-
ditional birth attendants, community health extension
workers and junior communityh e a l t he x t e n s i o nw o r k -
ers. Each wave would imply employment of 260-270 of
these health workers across the eight LGAs.
Analysis
In a spirit of social audit rather than primary causality
research, we are interested here in the whole package
working together. The concern is causality, but in the
sense of the impact of the intervention in real life, rather
than the efficacy of a specific intervention under ideal
conditions.
A 2006 systematic review of 12 stepped wedge con-
trolled trials found no two trials used the same analysis
approach [36]. Cluster randomised trials have two fea-
tures that distinguish them from individual randomised
trials. First, there can be positive intra-cluster correla-
tion between individuals’ target behaviour outcomes
within the same group. This can be due to the differ-
ences in characteristics between clusters or there may
be interaction between individuals within the same clus-
ter, particularly if there is a shared response to an inter-
vention experienced by the whole cluster. Second, given
that the intervention is delivered at the cluster level, the
most cost-efficient design is to randomise a relatively
small number of clusters to each intervention, and to
have a moderate or large number of participants per
cluster. This means we tend to overestimate the signifi-
cance of differences between intervention and control
waves.
Analysis in pipeline planning must acknowledge this. In
trails with a single measure of outcome, analysis is
straightforward. Among the commonly used analytic
methods, GLMM works well but requires assumptions
about the data distribution. GEE does not require these
assumptions but can be too liberal, as it does not address
inter-cluster variation. Feng and colleagues [37] recom-
mend permutation-based inference which avoids distri-
bution assumptions but it is not easy to explain to
general users and it is not for planners with a general
level of competence in statistics. For the social audit clus-
ter sample, we have adapted the venerated and easy to
explain Mantel Haenszel procedure, allowing for hetero-
geneity of effects across clusters with a robust odds ratio
estimate [38]. This produces similar results to GLMM
but without the assumptions or computational opacity.
The Hussey and Hughes [39] approach to stepped wedge
designs deals with changes over time in outcome vari-
ables and accounting for repeated measures on the same
individuals over the duration of the trial.
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Exchanges between protagonists of RCTs and others
who question their value and feasibility, have identified
several issues that merit consideration.
1. Controlled trials are not always enough, and not
always necessary to prove causality. The fact that an RCT
demonstrates a positive effect of an intervention does not
guarantee adoption of an intervention. Not all interven-
tions can be randomised. For interventions that can be
randomised, pipeline planning should not be about dis-
covery of causality. We should not start pipeline planning
without knowledge that the intervention should have a
positive effect. Pipeline planning is rather about the
amount of benefit from an intervention, its costs and side
effects in practice, in the spirit of social audit. In this set-
ting, randomisation is primarily about side-lining other
explanations for an association between coverage and a
change in health status, to focus on the number of cases
the intervention saves in real life.
In the many cases where it is not possible to implement
a new intervention or to reinforce existing interventions
everywhere at the same time, randomisation can also be
an equity issue. Assuming the intervention should even-
tually reach the whole country or region, random selection
of groups, clusters or communities to waves of interven-
tion gives everyone the same chance of early benefit (see
equity issues).
Randomised trials bring problems of their own, how-
ever, and these must be more than balanced by the
advantages before going ahead. Problems include con-
tamination, ambiguity of indicators, “participant effects”
that result from lack of blinding and lack of placebos,
ethics and, importantly, the skills to do them properly.
There is a positive side. Whereas analysis of linked cross
sectional observational studies can be really complex,
requiring considerable skill, analysis of a well designed
and well implemented RCCT is relatively simple.
2. Intervention development is not an automatic or
mechanical matter and communities do not always come
up with the most effective solutions. Some might claim
the government has to solve it for them. Others unrealisti-
cally expect a tertiary level hospital placed near them to
solve their problems. Our approach to social audit does
not view the epidemiologists as without knowledge. They
know some things, and their job is to bring what they
know to the table along with other expertise relevant to
the discussion. The intervention most likely to succeed is
likely to be supported in the literature or local knowledge.
It will have buy-in from community, services and planners.
Almost always, interventions require extensive piloting. In
our current pragmatic RCCT on reduction of choice dis-
ability related to HIV in three southern African countries
[40], piloting and packaging of just one of the three inter-
ventions took nearly two years. This development time
can be reduced and formalised, as we did in Nigeria, using
a proof-of-impact variant of social audit.
Timing of the impact requires consideration. In the
Nigerian initiative, we allow two years for an effect to
become measurable. As the women visited will be preg-
nant at the time of the visit, it is reasonable to conclude
that reduction in maternal morbidity will be within the
follow-up period. Many other interventions and out-
comes, however, have a less predictable relation with
time. Each step in a stepped wedge design may allow two
years, where the impact takes three or four years to
develop. This would lead planners wrongly to conclude
the intervention is ineffective.
3. Contamination is not limited to controlled trials.
The concern, in the Nigerian maternal morbidity exam-
ple, is that communities in the second wave hear about
the intervention and implement some of it. This
decreases the contrast between them and the first wave.
A similar dilution of measured effect happens if the inter-
vention is not properly implemented. The cluster inter-
vention design can help to reduce both effects. By using a
unit of randomisation, intervention and analysis that is
logistically and administratively coherent, spill over can
be minimised. In the Nigerian case, the unit of randomi-
sation and intervention is the local government authority
(LGA), which is coterminous with several crucial health
administrative functions. Although communities in
neighbouring LGAs may come to hear of the programme,
especially if it is successful, the effect of contamination is
likely to be much less than if individual households were
randomly allocated to intervention or control.
Perhaps the most famous and positive case of “contam-
ination” is the Framingham study of ischaemic heart dis-
ease. This successfully moved the focus of attention
“upstream” from specialist medical care to address the
underlying lifestyle causes. A crucial lesson from the Fra-
mingham experience was in the way results translated
rapidly and effectively into American and, some would
say, global culture [41]. The resulting contamination,
such that the Framingham cohort was not significantly
different from the rest of the USA, is probably the biggest
success of the initiative. It is impossible to avoid contami-
nation in successful interventions, if what we’re con-
cerned with is improved health, nor should we be
worried about it. What we should try to do, however, is
document (i) mechanisms for generalising evidence, (ii)
uptake at policy level and in the public discourse, (iii)
impact in the control sites.
The efficiency of implementing in a cluster – covering
100 contiguous households rather than 100 randomly
selected household scattered throughout the sample
domain – increases the likelihood of proper implementa-
tion within a limited budget. In practice, it cannot be
guaranteed that intervention and comparison groups are
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necessary to verify comparability.
Stepped wedge designs, where an intervention rolls out
to randomly selected waves of intervention groups or clus-
ters, can minimise spill over, as the incentive to migrate to
a different area just to benefit from the intervention is
counterbalanced by the fact that this intervention is going
to reach the entire study area within a known period of
time – there is a pipeline. This design also increases
understanding of the effect of time on the impact of an
intervention [42].
In pipeline planning, interventions are almost never
alone; they are in combination with existing interventions.
In the case of maternal mortality, there are several federal
and state government, NGO and private sector initiatives
to reduce maternal mortality. For control units to “learn”
from intervention units – LGAs in the Nigeria initiative –
they first would have to identify the specific components
and get involved with them. They might know there is a
video drama. They might even view it. But if they have not
discussed what they can do about it, in their community,
with other members of their community, they are unlikely
to implement the self-driven interventions that result from
this in the intervention communities.
4. Ambiguity of indicators and difficulty in defining the
measurement parameters are not solved by randomisation.
Using a similarly flawed indicator in both intervention and
control groups has at least the advantage that the error is
constant. But this does not make it a better indicator; this
task that must be tackled independent of study design.
Our approach to this, during the design stage, is to open a
consultation with the constituency – women, men, and
health workers – about their understanding of the issue
and their understanding of the terms. Rather than working
backwards from “our” instrument, we have found it worth-
while to elicit their way of viewing the issue using
approaches like fuzzy cognitive mapping (FCM) [43-45].
We have used FCM as an effective tool to review local
knowledge and beliefs around a community health issue,
contrasting the local belief system to that of Western
science. This can go on to inform various stages of the
research process, including the formulation of hypotheses,
questionnaire development, and even data analysis [46].
With the categories and concepts identified in a participa-
tory process, we first try to fit standard questions to each
concept. If this does not do the job, we have to do the
lengthy if interesting process of generating a new
indicator.
5. Blind, double blind and placebos: The concern is that
if people know they receive an intervention, as they cer-
tainly will do, they might change their behaviour because
they received an intervention, rather than because of the
specific content of the intervention. Blinding and placebos
are not the primary concerns of pragmatic trials. People
know that they are being vaccinated, or receiving a parti-
cular education regime in prenatal care, or attending a
particular health centre – the challenge is to be sure it is
not just this knowledge causing the effect. The easiest way
to do this is to include the knowledge of exposure as part
of the “package” getting tested. Pragmatic trials almost
always address a complex intervention: If we make this
vaccine available and promote its uptake through this or
that approach, what is the preventive effect? In relation to
male circumcision and HIV prevention, as another exam-
ple, one would examine the impact of a programme that
promotes circumcision; in an explanatory trial one would
be more concerned with HIV occurrence in men who had
accepted circumcision.
Placebos may be unnecessary and even unethical in the
public health context, but there is nothing unethical about
continuing or reinforcing current best practice in a control
group. Although it is not realistic to do an educational
intervention in one household and not in a neighbouring
household, it is entirely feasible to do the intervention in
one town, and not in another town. Efficacy trials have to
be careful that placebos and blindness are not mistaken
for trickery and deception. Pragmatic trials can bundle
consent with the intervention, providing information
about what the intervention is, its expected effects and
possible side effects. The public come forward to take it
up if they consent, and they do not if they do not consent.
6. Research ethics are a key issue in RCTs. Barahona
draws attention to the stringent ethical codes associated
with RCTs, and the need to get informed consent. He
argues that this is difficult in group settings, especially if
subjects are to remain blind to the exact intervention [47].
In pragmatic trials, consent is rarely the same issue as it is
in an explanatory trial. Pragmatic trials involve interven-
tions of proven efficacy, and an informational component
can and should contain all the information needed for
individual informed consent. Pragmatic trials are about
real life choices. People need information about the pros
and cons of any health service offer; then they can take it
up or decline to do so. In a programme pipeline, where all
communities will eventually benefit from the intervention,
having a random order adds an equity component without
the ethical dilemma of withholding a potentially beneficial
intervention.
7. Skills and infrastructure: Pipeline planning requires
redevelopment of the “info-structure” (information man-
agement and evidence synthesis behind planning) as an
agile and responsive tool, a living and flexible component
of planning able to combine qualitative and quantitative
evidence on different levels of prevention. The Nigerian
project provides this through the existing social audit
programme, which has strong acceptance from the
respective state governments of Bauchi and Cross River.
In most settings, this will require considerable additional
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capitals. The need for skills goes beyond advanced epide-
miology, though this is key. It includes appropriate use of
evidence, a respect for evidence, and an increasing ability
to distinguish between evidence and ideas. This content
can be the focus of a series of brief executive workshops,
involving parliamentarians and senior planners.
Conclusion
RCTs, efficacy or pragmatic, are not the answer to every
problem. Our next generation social audits draw on these
experimental methods in proof-of-impact and pipeline
planning not to discover causality, but to monitor impact
in a way that is relatively free of the constraints of observa-
tional studies.
Introduction of high level research methods into pro-
gramme roll out has multiple advantages, including
improving the programme in the pipeline, but it
requires a quantum shift in skills and sensibilities. In the
short and middle term, third party NGOs and universi-
ties can provide some of this. Sustainability will depend
on government buy in – which, in turn, depends on the
system showing its value in terms of money saved and
impact achieved.
Pipeline planning in its full application requires strong
and sustained government interest. This is typically least
p r e s e n ti ns i t u a t i o n st h a tw o u l dm o s tb e n e f i tf r o me v i -
d e n c e - b a s e dp l a n n i n g .As t e pi nt h er i g h td i r e c t i o n ,
making use of external support and the limited scale
this allows, is to implement a pragmatic RCCT in
selected sites across a jurisdiction like a state or country.
This allows for skill building to take it to scale and
increases buy-in based on feasibility and positive results.
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